Overcoming Resistance to Checkpoint Blockade Therapy by Targeting PI3K-γ in Myeloid Cells

Recent clinical trials using immunotherapy demonstrate its potential to control cancer by disinhibiting the immune system. Immune checkpoint blocking (ICB) antibodies such as anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-Programmed cell death protein 1/anti-Programmed death-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nature
Autors principals: De Henau, Olivier, Rausch, Matthew, Winkler, David, Campesato, Luis Felipe, Liu, Cailian, Cymerman, Daniel Hirschhorn, Budhu, Sadna, Ghosh, Arnab, Pink, Melissa, Tchaicha, Jeremy, Douglas, Mark, Tibbitts, Thomas, Sharma, Sujata, Proctor, Jennifer, Kosmider, Nicole, White, Kerry, Stern, Howard, Soglia, John, Adams, Julian, Palombella, Vito J, McGovern, Karen, Kutok, Jeffery L., Wolchok, Jedd D., Merghoub, Taha
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5634331/
https://ncbi.nlm.nih.gov/pubmed/27828943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature20554
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars